Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02093065 · ClinicalTrials.gov registry record
Platelet Function in Patients With Hemophilia A
A clinical trial, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- 36
- Enrollment target
NCT02093065 is a clinical trial that has completed, run by Boston Children's Hospital. The registered enrollment target is 36 participants.
The verdict
NCT02093065 has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
Abnormalities in the gene encoding Factor VIII (FVIII) results in hemophilia A, an X-linked recessive bleeding disorder with a prevalence of 1 in 5000 males. Hemophilia A patients are classified into 3 different categories based on residual FVIII activity compared to normal: mild (6-40%), moderate (1-5%) and severe (\<1%). This categorization correlates to some degree with bleeding phenotype, but does not completely define it. Some patients with hemophilia A bleed less often than others despite identical plasma FVIII levels. The cause(s) of this phenotype heterogeneity in hemophilia A remains largely unknown, despite a number of studies of possible factors. Activated platelets, in addition to their role in primary hemostasis, play a major role in secondary hemostasis (coagulation) by providing a phospholipid surface to which coagulation factors bind. A role for platelets in the hemorrhagic propensity of hemophilia A has been suggested in the past, but only a small number of studies have been performed with limitations in assays performed and numbers of patients. The purpose of the present study is to determine whether platelet reactivity in severe hemophilia A patients is associated with past bleeding frequency and/or predicts future bleeding frequency.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-03 |
| Est. Completion | 2020-02-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02093065
The ClinicalTrials.gov registry entry for NCT02093065 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02093065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02093065 about?
NCT02093065 is a clinical study titled "Platelet Function in Patients With Hemophilia A". Abnormalities in the gene encoding Factor VIII (FVIII) results in hemophilia A, an X-linked recessive bleeding disorder with a prevalence of 1 in 5000 males. Hemophilia A patients are classified into 3 different categories based on residual FVIII activity compared to normal: mild (6-40%), moderate (...
What is the current status of trial NCT02093065?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2015-03. Estimated completion is 2020-02-01.
Who is sponsoring clinical trial NCT02093065?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.